Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia.

Bone marrow transplantation - 1 Dec 2022

Song Ga-Young, Kim TaeHyung, Ahn Seo-Yeon, Jung Sung-Hoon, Kim Mihee, Yang Deok-Hwan, Lee Je-Jung, Choi Seung Hyun, Kim Mi Yeon, Jung Chul Won, Jang Jun-Ho, Kim Hee Je, Moon Joon Ho, Sohn Sang Kyun, Won Jong-Ho, Park Seong-Kyu, Kim Sung-Hyun, Zhang Zhaolei, Ahn Jae-Sook, Kim Hyeoung-Joon, Kim Dennis Dong Hwan

Abstract excerpt

Secondary-type mutations (STMs), namely SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, and STAG2, are more frequently detected in secondary acute myeloid leukemia (AML) than in de novo AML. Whether de novo AML with STMs should be differently managed is, however, unclear. In 394 patients diagnosed with de novo AML who had a normal karyotype, the genetic profiling via targeted deep sequencing of 45 genes revealed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cell Transplantation

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Prognosis

Share to Recurrence

Source

Identifiers

PMID: 36151367
DOI: 10.1038/s41409-022-01817-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia.PMID 36151367Read ↗

MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.Semantic proximity Read ↗

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.Semantic proximity Read ↗

Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia.Semantic proximity Read ↗

Recent Advances Towards the Understanding of Secondary Acute Myeloid Leukemia ProgressionSemantic proximity Read ↗

Genomic mutation patterns and prognostic value in de novo and secondary acute myeloid leukemia: A multicenter study from China.Semantic proximity Read ↗

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.Semantic proximity Read ↗

Genetic alteration patterns and clinical outcomes of elderly and secondary acute myeloid leukemia.Semantic proximity Read ↗

Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapseSemantic proximity Read ↗

Comparison of therapy‐related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group studySemantic proximity Read ↗

Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia.Semantic proximity Read ↗

Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based SettingSemantic proximity Read ↗

Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.